文献速递浆细胞疾病

肾功能不全患者复发骨髓瘤的治疗

Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency.
PubMed 文献 · J Clin Oncol · 2018-05-31

一例45岁男性IgG κ型多发性骨髓瘤患者,2010年3月确诊时伴多发溶骨性病变和T12椎体压缩,血清M蛋白72 g/L,血清肌酐1.6 mg/dL、eGFR 47 mL/min/1.73 m²,骨髓浆细胞58%伴17p缺失。经多线治疗及自体干细胞移植后复发,2014年10月血清M蛋白升至38.6 g/L、血清肌酐2.1 mg/dL、eGFR 41 mL/min/1.73 m²,本文讨论其后续治疗选择。

要点

  • 患者确诊时血清肌酐1.6 mg/dL、eGFR 47 mL/min/1.73 m²,复发时血清肌酐升至2.1 mg/dL、eGFR降至41 mL/min/1.73 m²。
  • 患者骨髓浆细胞58%且伴17p缺失,先后接受化疗、硼替佐米、来那度胺及自体干细胞移植。
  • 卡非佐米单药治疗获疾病稳定33个周期后,2014年10月出现疾病进展。

核心结论

  • 本文以一例伴肾功能不全的复发多发性骨髓瘤患者为例,讨论其诊断与治疗挑战并汇总作者建议的管理方法。

研究设计与样本

  • 肿瘤学大查房系列文章,以病例展示结合诊断与管理挑战描述、相关文献复习及作者建议的管理方法总结。

主要发现

  • 患者2010年3月确诊为III期IgG κ型多发性骨髓瘤,起病表现为多发溶骨性病变和T12椎体压缩所致骨痛。
  • 确诊时血清M蛋白72 g/L,24小时尿κ轻链蛋白排泄730 mg,血红蛋白10.2 g/dL,血清白蛋白49 g/L,血清β2微球蛋白6.4 mg/L。
  • 确诊时血清肌酐1.6 mg/dL、eGFR 47 mL/min/1.73 m²,血清钙和乳酸脱氢酶水平正常,骨髓浆细胞58%且伴17p缺失。
  • 患者接受椎体成形术及卡莫司汀、长春新碱、环磷酰胺、美法仑、泼尼松与长春新碱、卡莫司汀、多柔比星、地塞米松交替化疗。
  • 因疾病进展予硼替佐米联合地塞米松挽救治疗无反应,换用来那度胺联合地塞米松仅获微小缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 45-year-old man was diagnosed in March 2010 with stage III immunoglobulin G kappa multiple myeloma (MM) after presenting with bone pain as a result of multiple lytic bone lesions and T12 vertebral collapse. Laboratory work-up showed a serum M protein of 72 g/L and a 24-hour kappa light-chain urine protein excretion of 730 mg, hemoglobin of 10.2 g/dL, serum albumin of 49 g/L, serum β2-microglobulin of 6.4 mg/L, serum creatinine level of 1.6 mg/dL with an estimated glomerular filtration rate (eGFR) of 47 mL/min/1.73 m2, and normal serum calcium and lactate dehydrogenase (LDH) levels. His bone marrow contained 58% plasma cells, which showed the 17p deletion abnormality (Fig 1). He was treated with vertebroplasty and alternating chemotherapy with carmustine, vincristine, cyclophosphamide, melphalan, and prednisone and vincristine, carmustine, doxorubicin and dexamethasone. Because of progressive disease, salvage therapy with bortezomib and dexamethasone was administered with no response. The patient was then switched to lenalidomide and dexamethasone, which yielded minimal response. He underwent autologous stem-cell transplantation (ASCT) with melphalan 200 mg/m2 as high-dose therapy in February 2011, which led to a partial response, but in December 2011, progressive disease was documented, and the patient was enrolled in a clinical trial of carfilzomib monotherapy, with stable disease for 33 cycles. In October 2014 serum M protein rose to 38.6 g/L, with 24-hour kappa light-chain urine protein excretion of 840 mg, serum creatinine of 2.1 mg/dL, and an eGFR of 41 mL/min/1.73 m2. He presented to discuss ongoing treatment options.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bladé J, Rosiñol L, Cibeira MT, et al. Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. J Clin Oncol. 2018. PMID: 29851545. doi:10.1200/JCO.2017.77.6419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。